196 related articles for article (PubMed ID: 25669975)
81. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
[TBL] [Abstract][Full Text] [Related]
82. Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population.
Huang Q; Zhou Y; Wang B; Zhao Y; Zhang F; Ding B
BMC Med Genomics; 2022 Jul; 15(1):146. PubMed ID: 35778737
[TBL] [Abstract][Full Text] [Related]
83. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract][Full Text] [Related]
84. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing.
Wang J; Li R; Li J; Yi Y; Liu X; Chen J; Zhang H; Lu J; Li C; Wu H; Liang Z
J Transl Med; 2021 Oct; 19(1):433. PubMed ID: 34657620
[TBL] [Abstract][Full Text] [Related]
85. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
[TBL] [Abstract][Full Text] [Related]
86. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
[TBL] [Abstract][Full Text] [Related]
87. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
[TBL] [Abstract][Full Text] [Related]
88. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
89. Mutational analysis of anal cancers demonstrates frequent PIK3CA mutations associated with poor outcome after salvage abdominoperineal resection.
Cacheux W; Rouleau E; Briaux A; Tsantoulis P; Mariani P; Richard-Molard M; Buecher B; Dangles-Marie V; Richon S; Lazartigues J; Jeannot E; Farkhondeh F; Sastre-Garau X; de La Rochefordière A; Labib A; Falcou MC; Stevens D; Roth A; Roman-Roman S; Mitry E; Bièche I; Lièvre A
Br J Cancer; 2016 Jun; 114(12):1387-94. PubMed ID: 27219019
[TBL] [Abstract][Full Text] [Related]
90. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
91. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.
Li M; Jia H; Qian Q; Wen P; Chen C; Hua Y; Wang K; Zhang W; Shi F
Diagn Pathol; 2020 May; 15(1):49. PubMed ID: 32393293
[TBL] [Abstract][Full Text] [Related]
92. Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer.
Jia F; Teer JK; Knepper TC; Lee JK; Zhou HH; He YJ; McLeod HL
Mol Diagn Ther; 2017 Apr; 21(2):179-185. PubMed ID: 28039579
[TBL] [Abstract][Full Text] [Related]
93. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.
de la Rochefordiere A; Kamal M; Floquet A; Thomas L; Petrow P; Petit T; Pop M; Fabbro M; Kerr C; Joly F; Sevin E; Maillard S; Curé H; Weber B; Brunaud C; Minsat M; Gonzague L; Berton-Rigaud D; Aumont M; Gladieff L; Peignaux K; Bernard V; Leroy Q; Bieche I; Margogne A; Nadan A; Fourchotte V; Diallo A; Asselain B; Plancher C; Armanet S; Beuzeboc P; Scholl SM
Clin Cancer Res; 2015 Jun; 21(11):2530-7. PubMed ID: 25724520
[TBL] [Abstract][Full Text] [Related]
94. Genomic landscape of human papillomavirus-associated cancers.
Rusan M; Li YY; Hammerman PS
Clin Cancer Res; 2015 May; 21(9):2009-19. PubMed ID: 25779941
[TBL] [Abstract][Full Text] [Related]
95. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
De Grève J; Moran T; Graas MP; Galdermans D; Vuylsteke P; Canon JL; Schallier D; Decoster L; Teugels E; Massey D; Chand VK; Vansteenkiste J
Lung Cancer; 2015 Apr; 88(1):63-9. PubMed ID: 25682316
[TBL] [Abstract][Full Text] [Related]
96. Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
Zhao F; Xu M; Lei H; Zhou Z; Wang L; Li P; Zhao J; Hu P
PLoS One; 2015; 10(2):e0117333. PubMed ID: 25706305
[TBL] [Abstract][Full Text] [Related]
97. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.
Sohl CD; Ryan MR; Luo B; Frey KM; Anderson KS
ACS Chem Biol; 2015 May; 10(5):1319-29. PubMed ID: 25686244
[TBL] [Abstract][Full Text] [Related]
98. Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.
Ang D; Ballard M; Beadling C; Warrick A; Schilling A; O'Gara R; Pukay M; Neff TL; West RB; Corless CL; Troxell ML
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):97-103. PubMed ID: 25679062
[TBL] [Abstract][Full Text] [Related]
99. Left-sided early-onset vs late-onset colorectal carcinoma: histologic, clinical, and molecular differences.
Pilozzi E; Maresca C; Duranti E; Giustiniani MC; Catalanotto C; Lucarelli M; Cogoni C; Ferri M; Ruco L; Zardo G
Am J Clin Pathol; 2015 Mar; 143(3):374-84. PubMed ID: 25696795
[TBL] [Abstract][Full Text] [Related]
100. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
